- Public Comps
- Sartorius
Sartorius Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sartorius and similar public comparables like Steris, Divi's Laboratories, Wuxi Biologics, Halma and more.
Sartorius Overview
About Sartorius
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
Founded
1978
HQ

Employees
10.3K
Website
Financials (LTM)
EV
$23B
Valuation Multiples
Start free trialSartorius Financials
Sartorius reported last 12-month revenue of $3.6B and EBITDA of $1.1B.
In the same LTM period, Sartorius generated $1.7B in gross profit, $1.1B in EBITDA, and $407M in net income.
Revenue (LTM)
Sartorius P&L
In the most recent fiscal year, Sartorius reported revenue of $3.5B and EBITDA of $1.1B.
Sartorius is profitable as of last fiscal year, with gross margin of 44%, EBITDA margin of 31%, and net margin of 9%.
Financial data powered by Morningstar, Inc.
Sartorius Stock Performance
Sartorius has current market cap of $21B, and enterprise value of $23B.
Market Cap Evolution
Sartorius' stock price is $212.47.
Sartorius share price increased by 2.4% in the last 30 days, and by 4.6% in the last year.
Sartorius has an EPS (earnings per share) of $3.22.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23B | $21B | -0.9% | 2.4% | 16.0% | 4.6% | $3.22 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSartorius Valuation Multiples
Sartorius trades at 6.5x EV/Revenue multiple, and 20.9x EV/EBITDA.
EV / Revenue (LTM)
Sartorius Financial Valuation Multiples
As of July 19, 2026, Sartorius has market cap of $21B and EV of $23B.
Sartorius has a P/E ratio of 50.8x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sartorius Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Sartorius Margins & Growth Rates
Sartorius grew revenue by 3% and EBITDA by 4% in the last fiscal year.
In the most recent fiscal year, Sartorius reported gross margin of 44%, EBITDA margin of 31%, and net margin of 9%.
Sartorius Margins
Sartorius Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Sartorius Operational KPIs
Sartorius' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Sartorius' Rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sartorius' Rule of X is 48% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Sartorius Competitors
Sartorius competitors include Steris, Divi's Laboratories, Wuxi Biologics, Halma, Labcorp, Quest Diagnostics, Zimmer Biomet, Hologic, Medpace and Sonova.
Most Sartorius public comparables operate across Medical Devices, Laboratory Services, Contract Research & Manufacturing, DeepTech, HealthTech and BioTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.9x | 3.8x | 13.6x | 13.3x | |||
| 17.8x | 17.0x | 48.8x | 51.6x | |||
| 5.4x | 5.0x | 13.4x | 13.3x | |||
| 5.7x | 5.5x | 22.3x | 21.7x | |||
| 2.1x | 2.1x | 12.3x | 11.8x | |||
| 2.7x | 2.6x | 13.5x | 13.0x | |||
| 3.0x | 2.9x | 8.8x | 8.8x | |||
| - | - | - | - | |||
This data is available for Pro users. Sign up to see all Sartorius competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sartorius
| When was Sartorius founded? | Sartorius was founded in 1978. |
| Where is Sartorius headquartered? | Sartorius is headquartered in Germany. |
| How many employees does Sartorius have? | As of today, Sartorius has over 10K employees. |
| Who is the CEO of Sartorius? | Sartorius' CEO is Rene Faber. |
| Is Sartorius publicly listed? | Yes, Sartorius is a public company listed on Euronext Paris. |
| What is the stock symbol of Sartorius? | Sartorius trades under DIM ticker. |
| When did Sartorius go public? | Sartorius went public in 1994. |
| Who are competitors of Sartorius? | Sartorius main competitors include Steris, Divi's Laboratories, Wuxi Biologics, Halma, Labcorp, Quest Diagnostics, Zimmer Biomet, Hologic, Medpace, Sonova. |
| What is the current market cap of Sartorius? | Sartorius' current market cap is $21B. |
| What is the current revenue of Sartorius? | Sartorius' last 12 months revenue is $3.6B. |
| What is the current revenue growth of Sartorius? | Sartorius revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Sartorius? | Current revenue multiple of Sartorius is 6.5x. |
| What is the current EBITDA of Sartorius? | Sartorius' last 12 months EBITDA is $1.1B. |
| What is Sartorius' EBITDA margin? | Sartorius' last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Sartorius? | Current EBITDA multiple of Sartorius is 20.9x. |
| What is the current FCF of Sartorius? | Sartorius' last 12 months FCF is $386M. |
| What is Sartorius' FCF margin? | Sartorius' last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Sartorius? | Current FCF multiple of Sartorius is 59.7x. |
| How many companies Sartorius has acquired to date? | Sartorius hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Sartorius has invested to date? | Sartorius hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Sartorius
Lists including Sartorius
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




